Johnson & Johnson reported $15.2 billion in Q2 pharmaceutical sales, surpassing $15 billion for the first time despite a 43% decline in Stelara revenue due to biosimilar competition. Growth in oncology drugs, including $6.3 billion from cancer treatments and over half from multiple myeloma therapy Darzalex, provided significant uplift. The company's newer drug Tremfya showed 30% sales growth. J&J raised its 2025 operational growth forecast and reduced tariff-related cost impact estimates, driving over 6% stock gains.